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Abstract
Background: Triple negative breast cancer (TNBC) easily develops resistance to the first-line drug doxorubicin,
because of the high levels of the drug efflux transporter P-glycoprotein (Pgp) and the activation of pro-survival
pathways dependent on endoplasmic reticulum (ER). Interfering with these mechanisms may overcome the
resistance to doxorubicin, a still unmet need in TNBC.
Methods: We analyzed a panel of human and murine breast cancer cells for their resistance to doxorubicin, Pgp
expression, lysosome and proteasome activity, nitrite production, ER-dependent cell death and immunogenic cell death
parameters. We evaluated the efficacy of genetic (C/EBP-β LIP induction) and pharmacological strategies (lysosome and
proteasome inhibitors), in restoring the ER-dependent and immunogenic-dependent cell death induced by doxorubicin, in
vitro and in syngeneic mice bearing chemoresistant TNBC. The results were analyzed by one-way analysis of variance test.
Results:We found that TNBC cells characterized by high levels of Pgp and resistance to doxorubicin, had low induction of
the ER-dependent pro-apoptotic factor C/EBP-β LIP upon doxorubicin treatment and high activities of lysosome and
proteasome that constitutively destroyed LIP. The combination of chloroquine and bortezomib restored doxorubicin
sensitivity by activating multiple and interconnected mechanisms. First, chloroquine and bortezomib prevented C/EBP-β LIP
degradation and activated LIP-dependent CHOP/TRB3/caspase 3 axis in response to doxorubicin. Second, C/EBP-β LIP
down-regulated Pgp and up-regulated calreticulin that triggered the dendritic cell (DC)-mediated phagocytosis of tumor
cell, followed by the activation of anti-tumor CD8+T-lymphocytes upon doxorubicin treatment. Third, chloroquine and
bortezomib increased the endogenous production of nitric oxide that further induced C/EBP-β LIP and inhibited Pgp
activity, enhancing doxorubicin’s cytotoxicity. In orthotopic models of resistant TNBC, intratumor C/EBP-β LIP induction -
achieved by a specific expression vector or by chloroquine and bortezomib - effectively reduced tumor growth and Pgp
expression, increased intra-tumor apoptosis and anti-tumor immune-infiltrate, rescuing the efficacy of doxorubicin.
Conclusions:We suggest that preventing C/EBP-β LIP degradation by lysosome and proteasome inhibitors triggers multiple
virtuous circuitries that restore ER-dependent apoptosis, down-regulate Pgp and re-activate the DC/CD8+T-lymphocytes
response against TNBC. Lysosome and proteasome inhibitors associated with doxorubicin may overcome the resistance to
the drug in TNBC.
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Background
Triple negative breast cancer (TNBC) is often treated
with anthracycline (e.g. doxorubicin or daunorubicin)-
or taxane-based monotherapy [1], but the success is
lower than in other breast cancer types [2].
Doxorubicin kills tumor cells by inducing DNA damage,
increasing reactive oxygen and nitrogen species such as ni-
tric oxide (NO), impairing mitochondrial metabolism, indu-
cing endoplasmic reticulum (ER) stress and immunogenic
cell death (ICD) [3–5]. The main mechanism of
doxorubicin-induced ICD is the induction of ER stress, that
triggers the translocation of calreticulin (CRT) from the ER,
where it works as calcium sensor and chaperon, to the
plasma-membrane. Here, CRT promotes the phagocytosis
of tumor cells by dendritic cells (DC) and the activation of
a durable anti-tumor response by CD8+T-lymphocytes [6].
Doxorubicin’s efficacy is limited by the presence of drug
efflux transporters such as P-glycoprotein (Pgp) [7]. Pgp
limits the doxorubicin intracellular accumulation and the
drug’s ability to elicit pleiotropic cytotoxic effects.
Pgp expression is regulated by multiple transcription
factors. CAAT/enhancer binding protein (C/EBP)-β, a
transcription factor with two isoforms - C/EBP-β LAP
and LIP - that work as antagonists, is one of the main
controller of Pgp expression in solid tumors [5]. LAP is
activated during early ER stress, induces pro-survival
pathways and up-regulates Pgp; LIP is induced after pro-
longed ER stress, stimulates C/EBP homologous protein
(CHOP)/Tribbles 3(TRB3)/caspase 3-mediated apoptosis
[8] and down-regulates Pgp [9].
Besides a high expression, also a high activity of Pgp de-
termines doxorubicin resistance. Natural and synthetic in-
hibitors of Pgp [10, 11], liposomal formulations [12],
co-delivery of Pgp inhibitors plus doxorubicin [13], have
been tested to reduce Pgp activity in vitro and in preclinical
models, but until now none of these approaches were effect-
ive in patients. NO is a potent inhibitor of Pgp activity: this
molecule, released by synthetic NO donors or produced by
the endogenous NO synthase (NOS) enzymes, nitrates spe-
cific tyrosines that are critical for Pgp activity. Such covalent
modification reduces the doxorubicin efflux through Pgp
[14–16]. Curiously, doxorubicin increases the endogenous
production of NO, that mediates part of the cytotoxic ef-
fects of the drug [16], stimulates the translocation of CRT
and the ICD of tumor cell [17], induces ER stress [18, 19].
These events, however, occur only in doxorubicin-sensitive/
Pgp-negative cells, not in doxorubicin-resistant/Pgp-positive
ones [16, 17], leading to hypothesize that multiple
cross-talks determine a chemo-immune-resistant pheno-
type. Indeed, Pgp-positive cancer cells: i) do not accumulate
the intracellular amount of doxorubicin sufficient to in-
crease NO production [16] and induce ICD [17]; ii) do not
induce C/EBP-β LIP and ER stress-dependent cell death [5],
a condition necessary for the translocation of CRT on cell
surface and the subsequent ICD [3]; iii) are not phagocy-
tized by DC since Pgp hampers the immune-activating
functions of CRT in plasma-membrane [20].
Disrupting these vicious circles by decreasing Pgp
expression and activity is the only way to restore the multiple
cytotoxic mechanisms of doxorubicin. In this work we
demonstrated that preventing C/EBP-β LIP degradation and
increasing NO levels reduce at the same time expression and
activity of Pgp, restore the ER stress-dependent apoptosis
and the ICD induced by doxorubicin, rescuing the anthracy-
cline’s therapeutic efficacy in Pgp-positive TNBC.
Materials and methods
Chemicals and supplies
Plastic ware were obtained from Falcon (Becton Dickinson,
Franklin Lakes, NJ). Electrophoresis reagents were from
Bio-Rad Laboratories (Hercules, CA). The protein content
of cell lysates was assessed using the BCA kit from Sigma
Chemicals Co. (St. Louis, MO). Unless specified otherwise,
all reagents were purchased from Sigma Chemicals Co.
Cells
Human non-transformed breast epithelial MCF10A cells,
human breast cancer MCF7, SKBR3, T47D,
MDA-MB-231 cells, murine mammary cancer JC cells
were purchased from ATCC (Manassas, VA). Murine
mammary cancer TUBO cells were a kind gift of Prof.
Federica Cavallo, Department of Molecular Biotechnology
and Health Sciences, University of Torino, Italy. All hu-
man cells were authenticated by microsatellite analysis
using the PowerPlex kit (Promega Corporation, Madison,
WI; last authentication: January 2018). For 3D-cultures,
1 × 105 cells were seeded in 96-well plate coated with Bio-
mimesys™ matrix (Celenys, Rouen, France). Cells were
grown in DMEM/HAM F12 nutrient mixture medium
(MCF710A, MCF7, SKBR3, T47D), RPMI-1640 medium
(MDA-MB-231, JC), DMEM medium (TUBO) supple-
mented with 10% v/v fetal bovine serum (FBS) and 1% v/v
penicillin-streptomycin. Cells were checked for Myco-
plasma spp. contamination by PCR every three weeks;
contaminated cells were discharged.
Immunoblotting
Plasma-membrane proteins were isolated using the Cell
Surface Protein Isolation kit (ThermoFisher Scientific Inc.,
Waltham, MA) according to the manufacturer’s protocol.
For whole cell lysates, cells were rinsed with lysis buffer (50
mM Tris-HCl, 1mM EDTA, 1mM EGTA, 150mM NaCl,
1% v/v Triton-X100; pH 7.4), supplemented with the prote-
ase inhibitor cocktail III (Cabiochem, La Jolla, CA), soni-
cated and clarified at 13000×g, for 10min at 4 °C. Protein
extracts (20 μg) were subjected to SDS-PAGE and probed
with the following antibodies: anti-Pgp (1:250, rabbit poly-
clonal, #sc-8313, Santa Cruz Biotechnology Inc., Santa
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Cruz, CA), anti-multidrug resistant protein 1 (MRP1; 1:500,
mouse clone MRPm5, Abcam, Cambridge, UK), anti-breast
cancer resistance protein (1:500, mouse clone BXP-21,
Santa Cruz Biotechnology Inc.), anti-C/EBP-β (1:500, rabbit
polyclonal, # sc150, Santa Cruz Biotechnology Inc.),
anti-CHOP (1:500, mouse monoclonal, #ab11419, Abcam),
anti-TRB3 (1:500, rabbit polyclonal, #13300–1-AP, Protein-
tech, Chicago, IL), anti-caspase-3 (1:1000, mouse clone
C33, GeneTex, Hsinhu City, Taiwan), anti-CRT (rabbit
polyclonal #PA3–900, Affinity Bioreagents, Rockford, IL),
anti-NOS I (1:500, mouse clone 16, BD Biosciences, Frank-
lin Lakes, NJ), anti-NOS II (1:1000, mouse clone 4E5, Ther-
moFisher Scientific Inc.), anti-NOS III (1:500, mouse clone
3, BD Biosciences), anti-pancadherin (1:500, goat clone
C-19, Santa Cruz Biotechnology Inc.), anti-β-tubulin
(1:1000, mouse clone D10, Santa Cruz Biotechnology Inc.),
followed by the horseradish peroxidase-conjugated second-
ary antibodies (Bio-Rad). The membranes were washed
with Tris-buffered saline (TBS)/Tween 0.01% v/v. To detect
ubiquitinated C/EBP-β, 100 μg of proteins from whole cell
lysates were immuno-precipitated overnight with the
anti-C/EBP-β antibody, then probed with an anti-mono/
poly-ubiquitin antibody (1:1000, mouse clone FK2, Axxora,
Lausanne, Switzerland), using 50 μl of PureProteome Mag-
netic Beads (Millipore, Bedford, MA). To detect nitrated
Pgp, 100 μg of proteins from plasma-membrane were
immuno-precipitated overnight with anti-nitrotyrosine
antibody (1:50, rabbit polyclonal, #06–284, Millipore), then
probed with the anti-Pgp antibody. Proteins were detected
by enhanced chemiluminescence (Bio-Rad Laboratories).
Blot images were acquired with a ChemiDocTM Touch
Imaging System device (Bio-Rad Laboratories). The densi-
tometric analysis was performed with the ImageJ software
(https://imagej.nih.gov/ij).
Lysosome and proteasome activities
The activity of cathepsin L, an index of lysosome activity,
was measured according to [21]. The results were
expressed as nmoles/mg cellular proteins. Proteasome ac-
tivity was measured with the Proteasome-Glo™ Cell-Based
Assays (Promega Corporation). The results were expressed
as relative luminescence units (RLU)/mg cellular proteins.
Cell viability
1 × 104 cells were seeded in 96-well plate and incubated as
described in the experimental section for 72 h. To calculate
the IC50, cells were treated with doxorubicin at scalar con-
centrations (from 10− 10 to 10− 3M). Viability was measured
with the ATPLite Luminescence Assay kit (PerkinElmer,
Waltham, MA) as per manufacturer’s instructions. The via-
bility in untreated cells was considered as 100%. The results
were expressed as percentage of viable cells towards the un-
treated cells. The IC50 was calculated with the CompuSyn
software (http://www.combosyn.com).
Doxorubicin accumulation and efflux
The intracellular doxorubicin content and the drug ef-
flux were measured as detailed in [16]. The intracellular
doxorubicin concentration was expressed as nanomoles
of doxorubicin/mg cellular proteins. The efflux of doxo-
rubicin was expressed as the change in the intracellular
concentration of the drug/minute (dc/dt).
Pgp ATPase activity
The Pgp ATPase activity was measured in Pgp-rich
membrane vesicles as described in [22]. The results were
expressed as μmol hydrolyzed phosphate/min/mg mem-
brane proteins.
Nitrite production and NOS activity
The production of nitrite, the stable derivative of NO, was
measured spectrophotometrically by the Griess methods,
as described in [23]. Nitrite concentration was expressed
as nanomoles/min/mg cellular proteins. The activity of
NOS in cell lysates was measured using the Ultrasensitive
Colorimetric Assay for Nitric Oxide Synthase kit (Oxford
Biomedical Research, Oxford, MI), as per manufacturer’s
instructions. The enzyme activity was expressed as nano-
moles of nitrites/min/mg cellular proteins.
Immunofluorescence analysis
5 × 105 2D-cells were grown onto glass coverslips in
24-well plates overnight; the same number of cells was
seed to produce 3D-cultures, analyzed after 1 week.
Sample were fixed using 4% w/v paraformaldehyde
(PFA) for 15 min at room temperature, washed with
PBS, incubated for 1 h at 4 °C with an anti-Pgp antibody
(1:50, mouse clone JSB-1; Abcam, diluted in 1% FBS/
PBS), washed five times with PBS and incubated for 1 h
at room temperature with an AlexaFluor488-conjugated
secondary antibody (Abcam, diluted 1:50 in 1% FBS/
PBS). Cells were incubated with 4′,6-diamidino-2-phe-
nylindole dihydrochloride (DAPI), diluted 1:10000 in
PBS for 5 min, washed four times with PBS and once
with deionized water. The cover slips were mounted
with the Gel Mount Aqueous Mounting and examined
with a Leica DC100 fluorescence microscope (Leica
Microsystems GmbH, Wetzlar, Germany). For each ex-
perimental point, a minimum of five microscopic fields
were examined.
Over-expression of C/EBP-β LAP and LIP
The pcDNA4/TO expression vectors (Invitrogen Life
Technologies, Milan, Italy) for LAP and LIP, produced
as reported previously [8], were co-transduced with
pcDNA6/TR vector (Invitrogen Life Technologies) in
parental cells. Doxycycline-inducible (TetON) stable
clones were generated by selecting cells with 2 μg/ml
blasticidin S (Invitrogen Life Technologies) and
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100 μg/ml zeocin (InvivoGen, San Diego, CA). LIP in-
duction was activated by adding 1 μg/ml doxycycline
in the culture medium.
Quantitative real time-PCR (qRT-PCR)
Total RNA was extracted and reverse-transcribed using the
iScriptTM cDNA Synthesis Kit (Bio-Rad Laboratories).
qRT-PCR was performed using the IQ™ SYBR Green Super-
mix (Bio-Rad Laboratories). The following PCR primer se-
quences were designed using the qPrimerDepot software
(http://primerdepot.nci.nih.gov/): Pgp (human): 5’-TGCT
GGAGCGGTTCTACG-3′, 5’-ATAGGCAATGTTCTCAG
CAATG-3′; Pgp (mouse): 5’-TGCTTATGGATCCCAGAGT
GAC-3′, 5’-TTGGTGAGGATCTCTCCGGCT-3’;CRT (hu-
man): 5’-TGTCAAAGATGGTGCCAGAC-3′, 5’-ACAACC
CCGAGTATTCTCCC-3′; CRT (mouse): 5’-TACAAGGGC
GAGTGGAAACC-3′, 5’-GCATCGGGGGAGTATTCAG
G-3′; S14 (human): 5’-CGAGGCTGATGACCTGTTCT-3′,
5’-GCCCTCTCCCACTCTCTCTT-3′; S14 (mouse): 5’-TC
TGGGATGAAGATTGGGCG-3′, 5’-ACCCCCTTTTCT
TCGAGTGC-3′. The relative gene expression levels were
calculated using the Gene Expression Quantitation software
(Bio-Rad Laboratories).
Chromatin immunoprecipitation (ChIP)
The putative binding sites of C/EBP-β, containing CAAT
box motif, on human and murine CRT promoter were iden-
tified using the Gene Promoter Miner software (http://gpmi-
ner.mbc.nctu.edu.tw/). The following primers were designed
with the Primer3 software (http://primer3.ut.ee/): 5′-TGGG
GAGGTGGAGTAGAGTG-3′; 5’-CAGGAACTGCAGGG
ACTGAG-3′ (site 831–843, human CRT promoter);
5’-CTCACAGGTCTCGCCTTGTC-3′; 5’-ATGCACTGTT
CCGACGTTC-3′ (site 1302–1313, human CRT promoter);
5’-CCTAGCGAGCCAGAGACTC-3′; 5’-CTATTGGTCGC
ACTATGGGC-3′ (site 798–811, mouse CRT promoter);
5’-GCCTAACTTGCTGAGCCAAC-3′; 5’-CTACCTCTCA
CCCGAACCTG-3′ (site 872–883, mouse CRT promoter).
To determine the binding of LAP and LIP to CRT promoter,
ChIP was performed as described in [24].
Flow cytometry analysis
1 × 105 cells were washed with PBS, detached with Cell
Dissociation Solution, wash twice with PBS, incubated for
45min at 4 °C with the anti-CRT antibody, diluted 1:100
in 0.25% v/v bovine serum albumin (BSA)-PBS, followed
by the AlexaFluor488-conjugated secondary antibody
(1:50) for 30min at 4 °C. After the fixation step in 2.5% v/
v PFA for 5min at room temperature, samples were ana-
lyzed with a Guava® EasyCyte flow cytometer (Millipore)
equipped with the InCyte software (Millipore). Cells incu-
bated with not-immune isotype antibody, followed by sec-
ondary antibody, were include as control of specificity.
Tumor cells phagocytosis and T-lymphocytes activation
DC were generated from monocytes immuno-magnetically
isolated from peripheral blood of healthy donors, provided
by Blood Bank of AOU Città della Salute e della Scienza,
Torino, Italy as previously reported [25] or from the bone
marrow of 6-week old female balb/C mice [26]. The phago-
cytosis assay was performed as detailed in [26], by
co-incubating DC and tumor cells at 37 °C and 4 °C for 24
h. The percentage of phagocytized cells obtained after the
incubation at 4 °C was subtracted from the percentage ob-
tained at 37 °C, and was always less than 5% (not shown).
The phagocytosis rate was expressed as phagocytic index
[26]. After cell phagocytosis, DC were washed and
co-cultured for 10 days with autologous T-cells, isolated by
immuno-magnetic sorting with the Pan T Cell Isolation Kit
(Miltenyi Biotec., Tetrow, Germany). The expression of
CD107, a degranulation marker and an index of active cyto-
toxic CD8+T-lymphocytes, was determined by flow cytome-
try as previously reported [25], using anti-human or mouse
fluorescein isothyocyanate (FITC)-conjugated-CD8 (1:10,
clones BW135/80 and 53–6.7) and phycoerythrin (PE)-con-
jugated-CD107 (1:10, clones H4A3 and 1D4B) antibodies
(Miltenyi Biotec).
Cell silencing
1 × 105 cells were treated with 10 nM of 3 unique 27mer
siRNA duplexes, targeting DDIT3/CHOP (#SR319903;
Origene, Rockville, MD) or with a Trilencer-27 Universal
scrambled negative control siRNA duplex (#SR30004;
Origene), as per manufacturer’s instructions. The effi-
ciency of silencing was verified by immunoblotting.
Calreticulin knock-out (KO)
JC cells were knocked-out for calreticulin using a pool of
two calreticulin-targeting CRISPR/Cas9 KO-green fluores-
cence protein (GFP) vectors (#KN302469, Origene).
Non-targeting (scrambled) CRISPR/Cas9 vector (Origene)
was used as control of specificity. 1 × 105 cells were seeded
in antibiotic-free medium. 1 μg of CRISPR/Cas9 plasmid
was used, as per manufacturer’s instructions. Transfected
cells were sorted by isolating GFP-positive cells. KO effi-
cacy was verified by immunoblotting. Stable KO-clones
were generated by culturing cells for 6 weeks in medium
containing 1 μg/ml puromycin.
In vivo tumor growth
1 × 107 JC TetON LIP cells, wild-type, stably transfected
with a KO-CRT vector or with a scrambled vector, were
mixed with 100 μl Matrigel and orthotopically implanted in
6 week-old female immunocompetent balb/C mice (Charles
River Laboratories Italia, Calco), housed (5 per cage) under
12 h light/dark cycle, with food and drinking provided ad
libitum. Tumor growth was measured daily by caliper, ac-
cording to the equation (LxW2)/2, where L = tumor length
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and W= tumor width. When tumor reached the volume of
50mm3, mice were randomized and treated as reported in
the experimental section. Tumor volumes were monitored
daily. Animals were euthanized at day 21 after
randomization with zolazepam (0.2ml/kg) and xylazine
(16mg/kg). Lactate dehydrogenase, aspartate aminotrans-
ferase, alanine aminotransferase, alkaline phosphatase, cre-
atinine, creatine phosphokinase and troponin were
measured on blood samples collected immediately after eu-
thanasia, using commercially available kits from Beckman
Coulter Inc. (Beckman Coulter, Miami, FL). In all studies,
researchers analyzing the results were unaware of the treat-
ments received by animals.
Immunohistochemistry analysis
Tumors were resected and fixed in 4% v/v PFA, photo-
graphed and sectioned, then stained with hematoxylin/
eosin or immuno-stained for Ki67 (1:50, rabbit polyclonal
#AB9260, Millipore), Pgp (1:50), CHOP (1:50), cleave-
d(Asp175)-caspase 3 (1:200, rabbit polyclonal #9661, Cell
Signaling Technology Inc., Danvers, MA), CRT (1:100),
CD11c (1:50, hamster, clone HL3, BD Biosciences) to label
intra-tumor DC, CD8 (1:100, rat clone YTS169.4, Abcam)
to label intra-tumor cytotoxic T-lymphocytes, followed by a
peroxidase-conjugated secondary antibody (1:100, Dako,
Glostrup, Denmark). Sections were examined with a Leica
DC100 microscope.
IFN-γ production
Tumor-draining lymph nodes were collected, homogenized
for 30 s at 15Hz using a TissueLyser II device (Qiagen, Hil-
den, Germany) and centrifuged at 12000×g for 5min. The
supernatant was collected to measure the amount of IFN-γ,
using the Mouse IFN-γ DuoSet ELISA Kit (R&D Systems,
Minneapolis, MN). The results were expressed as nmol/ml.
Statistical analysis
All data in the text and figures are provided as means
±SD. The results were analysed by a one-way analysis of
variance (ANOVA), using the Statistical Package for So-
cial Science (SPSS) software (IBM, Armonk, NY). p <
0.05 was considered significant.
Results
Pgp-positive breast cancer cells do not induce C/EBP-β
LIP upon doxorubicin treatment and have high lysosome
and proteasome activities
The analysis of ABC transporters (Pgp, MRP1, BCRP) in-
volved in doxorubicin efflux in epithelial mammary
MCF10A cells and in a panel of breast cancer cell lines in-
dicated a higher expression of Pgp in TNBC human
MDA-MB-231cells, and in murine JC and TUBO cells.
Pgp levels were further increased by doxorubicin expos-
ure. None cell line expressed MRP1, except TUBO cells,
without changes induced by doxorubicin. BCRP levels
were undetectable or very low (Fig. 1a). The pattern of
Pgp expression was in accord with the IC50 to doxorubicin
of each cell line (Additional file 1). Either untreated or
doxorubicin-treated cells expressed C/EBP-β LAP. C/
EBP-β LIP was induced by doxorubicin in epithelial
MCF10A cells and in Pgp-negative breast cancer MCF7,
SKBR3, and T47D cells, while Pgp-positive
MDA-MB-231, JC and TUBO cells had a lower C/EBP-β
LIP induction (Fig. 1b). These three cell lines had higher
lysosome (Fig. 1c) and proteasome (Fig. 1d) activities com-
pared to doxorubicin-sensitive/Pgp-negative cells. The
amount of LIP induced upon doxorubicin treatment was
inversely correlated with the lysosome (Fig. 1e) and prote-
asome (Fig. 1f) activity in the cell lines examined, suggest-
ing that – as observed for other solid tumors [5, 27] – the
degradation via lysosome and proteasome is critical in
preserving C/EBP-β LIP level in breast cancer.
Doxorubicin resistance is associated to the lack of C/EBP
LIP-β-dependent apoptosis in breast cancer cells
We thus examined if the FDA-approved lysosome inhibitor
chloroquine and proteasome inhibitor bortezomib could
prevent C/EBP-β LIP degradation. In preliminary
dose-dependence experiments, we determined that at 1 μM
chloroquine and bortezomib - used as single agents - did
not reduce significantly cell viability (Additional file 2), but
they decreased lysosome (Additional file 3a) and prote-
asome (Additional file 3b) activities, respectively, in
Pgp-positive MDA-MB-231 and in JC cells. When used in
combination, chloroquine and bortezomib significantly de-
creased the viability of these cell lines (Additional file 2).
In Pgp-negative MCF10A, MCF7, SKBR3 or T47D cells,
which accumulated higher amount of doxorubicin compared
to MDA-MB-231, JC or TUBO cells, the combination of
chloroquine and bortezomib did not increase the drug con-
tent (Fig. 2a) nor enhanced the anti-proliferative effects of
doxorubicin (Fig. 2b). By contrast, chloroquine and bortezo-
mib, in particular when used in combination, significantly in-
creased doxorubicin accumulation (Fig. 2a) and cytotoxicity
(Fig. 2b) in Pgp-positive MDA-MB-231, JC and TUBO cells.
For the following investigations, we focused on the TNBC
human MDA-MB-231 cells and on murine JC cells, i.e. the
cell lines characterized by the highest expression of Pgp, the
lowest induction of C/EBP-β LIP, the highest lysosome and
proteasome activities (Fig. 1a-c). In both cell lines, chloro-
quine and bortezomib increased C/EBP-β LIP and the
LIP-dependent CHOP/TRB3/caspase 3 axis, while doxorubi-
cin did not. The induction of C/EBP-β LIP/CHOP/TRB3/
caspase 3 axis was stronger in cells treated with chloroquine
and bortezomib followed by doxorubicin (Fig. 2c). These re-
sults suggest that chloroquine, bortezomib and doxorubicin
cooperate each other in increasing C/EBP-β LIP and the
downstream pro-apoptotic CHOP/TRB3/caspase 3 axis.
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Chloroquine and bortezomib down-regulate Pgp
expression and activity by increasing C/EBP-β LIP and NO
NOS I and NOS III constitutively produce NO, while
NOS II is induced upon inflammation [28] or doxorubi-
cin in drug-sensitive cells [16]. MDA-MB-231 and JC
cells basally express NOS I and NOS III, while NOS II
was undetectable (Fig. 3a).
It has been previously reported that NOS I expression is
increased by the inhibition of proteasome [29], while NOS
III activity is increased by chloroquine [30]: indeed, the
Fig. 1 Doxorubicin induces C/EBP-β LIP in Pgp-negative but not in Pgp-positive breast cancer cells. Cells were cultured in the absence (−) or presence
(+) of 5 μM doxorubicin (dox) for 24 h. a. Plasma-membrane extracts were probed with the indicated antibodies. The expression of pancadherin was
used as control of equal protein loading. The figure is representative of 1 out of 3 experiments. b. Whole cell lysates were probed with an antibody
recognizing both C/EBP-β LAP and LIP isoforms. The expression of β-tubulin was used as control of equal protein loading. The figure is representative
of 1 out of 3 experiments. c-d. Lysosome activity (panel c) was analyzed in duplicates by a spectrophotometric assay, proteasome activity (panel d)
was analyzed in duplicates by a chemiluminescence-based assay. Data are presented as means±SD (n = 3). e-f. Correlation between LIP band density
upon doxorubicin treatment (panel b) and lysosome (panel c) or proteasome (panel d) activities. The mean band density of LIP was expressed as
arbitrary units using the ImageJ software, setting the mean band density in MCF10A cells as 1
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lysosome inhibitor lowers the availability of intracellular
free iron [31]; this condition increases NOS III activity
without changing its expression [30]. In line with these
findings, bortezomib, alone or in combination with
chloroquine, increased NOS I expression, while chloro-
quine did not alter the expression of any NOS isoform
(Fig. 3a). The use of the proteasome activator betulinic
acid suggested that the up-regulation in NOS I induced by
bortezomib was mediated by the inhibition of proteasome
activity (Fig. 3a). Both chloroquine and bortezomib, alone
and in particular in combination, increased the activity of
NOS enzymes and the production of nitrite, the stable de-
rivative of NO (Fig. 3b; Additional file 4). This trend can
be due either to the increased expression of NOS I in-
duced by bortezomib (Fig. 3a) or to the increased activity
of NOS III induced by chloroquine [30].
Since NO induces ER stress [19], we performed the
following add-back experiments in order to investigate
Fig. 2 Chloroquine and bortezomib restore doxorubicin accumulation, cell death and C/EBP-β LIP induction in Pgp-positive cells. Cells were
cultured in the absence (ctrl) or presence of the lysosome inhibitor chloroquine (CQ; 1 μM), the proteasome inhibitor bortezomib (B; 1 μM), or
their combination, for 24 h (panels a-c) or 72 h (panel b). Doxorubicin (dox; 5 μM) was added for additional 24 h (panels a-c) or in the last 48 h
(panel b). a. Doxorubicin accumulation was measured in triplicates by a fluorimetric assay. Data are presented as means±SD (n = 3). *p < 0.01:
treated cells vs ctrl cells; °p < 0.001: CQ + B-treated cells vs CQ/B-treated cells. b. Cell viability was measured in quadruplicates by a
chemiluminescence-based assay. Data are presented as means±SD (n = 3). *p < 0.02: treated cells vs “- dox ctrl” cells; °p < 0.02: treated cells vs “+
dox ctrl” cells; #p < 0.005: CQ + B-treated cells vs CQ/B-treated cells. c. Whole cell lysates were probed with the indicated antibodies. The
expression of β-tubulin was used as control of equal protein loading. The figure is representative of 1 out of 3 experiments
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Fig. 3 Chloroquine and bortezomib induce C/EBP-β LIP/CHOP/TRB3/caspase 3 axis by increasing NO levels. MDA-MB-231 and JC cells were cultured
for 24 h in the absence (ctrl, −) or presence (+) of the lysosome inhibitor chloroquine (CQ; 1 μM) or of the proteasome inhibitor bortezomib (B; 1 μM),
alone or in combination. When indicated, the lysosome activator torin-1 (To; 1 μM) or the proteasome activator betulinic acid (BA; 10 μM) were added.
a.Whole cell lysates were probed for NOS I, NOS II, NOS III. The expression of β-tubulin was used as control of equal protein loading. The figure is
representative of 1 out of 3 experiments. b. The activity of NOS enzyme in cell lysate and the levels of nitrite in the supernatants were measured in
triplicates by spectrophotometric assays. Data are presented as means±SD (n = 3). *p < 0.05: treated cells vs ctrl cells; °p < 0.02: CQ + B-treated cells vs
CQ/B-treated cells. c. MDA-MB-231 cells were cultured for 24 h in the absence (−) or presence (+) of the lysosome inhibitor chloroquine (CQ; 1 μM),
the proteasome inhibitor bortezomib (B; 1 μM), the lysosome activator torin-1 (To; 1 μM), the proteasome activator betulinic acid (BA; 10 μM), the NO
donor sodium nitroprusside (SNP; 10 μM), the NO scavenger carboxy-PTIO (PTIO; 100 μM), alone or co-incubated in different combinations. Whole cell
lysates were immunoprecipitated (IP) with the anti-C/EBP-β antibody, which recognizes both C/EBP-β-LAP and C/EBP-β-LIP, then immunoblotted (IB)
with the anti-mono/poly-ubiquitin (UQ) antibody; alternatively, lysates were directly immunoblotted with the indicated antibodies. No Ab: lysate from
untreated cells immunoprecipitated in the absence of the anti-C/EBP-β antibody, as control of specificity. The expression of β-tubulin was used as
control of equal protein loading before immunoprecipitation. The figure is representative of 1 out of 3 experiments
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whether chloroquine and bortezomib up-regulated C/
EBP-β LIP by inhibiting lysosomal and proteasomal ac-
tivity, by increasing NO production or by both
mechanisms.
In a first experimental set, we co-incubated chloroquine
and bortezomib with the lysosome activator torin-1 or the
proteasome activator betulinic acid. As shown in Fig. 3c
and Additional file 5, in both MDA-MB-231 and JC cells,
torin-1 reduced the induction of C/EBP-β LIP/CHOP/
TRB3/caspase 3 axis elicited by chloroquine, alone or com-
bined with bortezomib. Since torin-1 did not affect the ubi-
quitination of C/EBP-β LIP, its effect was likely due to the
activation of the LIP degradation via lysosome. Betulinic
acid reduced the up-regulation of C/EBP-β LIP and down-
stream effectors induced by bortezomib, alone or associated
with chloroquine. Of note, betulinic acid also reduced the
levels of poly-ubiquitinated LIP, indicating that if favored
the removal of ubiquitinated LIP via proteasome.
In a second experimental set, we used the NO donor so-
dium nitroprusside (SNP), which increased nitrite, and the
NO scavenger carboxy-PTIO, which reduced the amount of
nitrite in untreated, chloroquine- and bortezomib-treated
cells (Additional file 4). SNP increased C/EBP-β LIP levels
and CHOP/TRB3/caspase 3 axis activation, while the
co-incubation with carboxy-PTIO abrogated these events
(Fig. 3c; Additional file 5), suggesting the increased levels of
NO may trigger the induction of LIP and ER-dependent
apoptotic cascade. Of note, PTIO also reduced the increase
in nitrite (Additional file 4) and in C/EBP-β LIP/CHOP/
TRB3/caspase 3 axis in cells co-incubated with chloroquine
and bortezomib (Fig. 3c; Additional file 5). We did not find a
further enhancement of nitrite or C/EBP-β LIP/CHOP/
TRB3/caspase 3 up-regulation in cells treated with SNP,
chloroquine and/or bortezomib compared to cells treated
with SNP alone (Fig. 3c; Additional files 4, 5), suggesting that
in these experimental conditions the level of NO released by
SNP was likely saturating and sufficient to reach the maximal
C/EBP-β LIP induction.
Overall these results suggest that either the inhibition
of lysosome and proteasome activity or the increase in
endogenous NO mediate the induction of C/EBP-β LIP
exerted by chloroquine and bortezomib.
Since C/EBP-β LIP [5] and NO [14, 15] decrease Pgp ex-
pression and activity, respectively, we investigated whether
the increase in C/EBP-β LIP and NO levels achieved by
chloroquine and bortezomib may reduce the efflux of doxo-
rubicin via Pgp. Chloroquine, bortezomib or their combin-
ation reduced Pgp mRNA (Fig. 4a) and protein (Fig. 4b) in
both MDA-MB-231 and JC cells, in accord with the tran-
scriptional repression of Pgp exerted by LIP [9]. Moreover
the lysosome and proteasome inhibitors increased the
amount of nitrated - i.e. less active [14, 15] - Pgp on cell sur-
face (Fig. 4b). Consistently, chloroquine and bortezomib, in
particular if used in combination, when they maximally
increased C/EBP-β LIP and NO levels (Fig. 3b-c), significantly
decreased the Pgp ATP-ase activity (Fig. 4c) and the rate of
doxorubicin efflux (Fig. 4d).
To verify if the same chemosensitizing effects were main-
tained in 3D-cultures, a model closer to the in vivo tumor
biology and characterized by higher Pgp expression and
doxorubicin resistance compared to 2D-cultures [32], we
produced 3D-cultures of T47D cells, which were
Pgp-negative (Fig. 1a) and doxorubicin-sensitive (Fig. 2b)
cells when grown bi-dimensionally. T47D-3D cells in-
creased the expression of Pgp (Additional file 6a), reduced
the intracellular doxorubicin retention (Additional file 6b),
increased the cell viability in the presence of doxorubicin
(Additional file 6c) and lost the ability to induce C/EBP-β
LIP in response to the drug (Additional file 6d), behaving
like the doxorubicin-resistant/Pgp-positive MDA-MB-231
cells. 3D-cultures had higher lysosome (Additional file 6e)
and proteasome (Additional file 6f) activities than
2D-cultures, but they retained the sensitivity to chloroquine
and bortezomib. Indeed these two agents reproduced the
same effects observed in doxorubicin-resistant/Pgp-positive
MDA-MB-231 cells: they increased C/EBP-β LIP/CHOP/
TRB3/caspase 3 pathway (Additional file 6 g), decreased
Pgp mRNA and protein (Additional file 6 g-h), increased
Pgp nitration (Additional file 6 g) in consequence of the in-
creased production of NO (Additional file 6i), restored the
intracellular accumulation (Additional file 6j) and cytotox-
icity of doxorubicin (Additional file 6 k) to the same levels
of doxorubicin-sensitive T47D-2D cells.
C/EBP-β LIP restores doxorubicin-induced immunogenic
cell death in resistant breast cancer cells
Since in malignant pleural mesothelioma C/EBP-β LIP
transcriptionally activates CRT [27], one of the main
ICD effector, we next investigated whether the absent in-
duction of C/EBP-β LIP upon doxorubicin treatment
also reduced the pro-immunogenic effects of the anthra-
cycline in resistant TNBC cells. To this aim, we select-
ively over-expressed C/EBP-β LAP or C/EBP-β LIP in
MDA-MB-231 cells (Fig. 5a). C/EBP-β LIP, but not LAP,
was bound to the site 831–843 of CRT promoter (Fig.
5b). C/EBP-β LIP-overexpressing cells had increased
CRT mRNA (Fig. 5c), total (Fig. 5d) and surface CRT
(Fig. 5e) protein compared with cells transfected with
empty vector or overexpressing C/EBP-β LAP. The in-
crease in CRT was paralleled by the increased
DC-mediated tumor cell phagocytosis (Fig. 5f ) and by
the increased expansion of CD8+CD107+T-lymphocytes
incubated with DC that have phagocytized tumor cells
(Fig. 5g). The same phenotype was obtained in JC cells
transfected with a TetON C/EBP-β LIP-expression vec-
tor (Additional file 7a-g).
The combined pharmacological inhibition of lysosome
and proteasome in TetON MDA-MB-231 cells - also in
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the absence of doxycycline - induced C/EBP-β LIP pro-
tein (Additional file 8a-b), increased LIP binding to CRT
promoter (Fig. 6a), CRT mRNA (Fig. 6b) and protein
(Fig. 6c-d) levels, tumor cell phagocytosis (Fig. 6e) and
CD8+CD107+T-lymphocytes expansion (Fig. 6f ). Con-
sistently with the resistance of MDA-MB-231 cells,
doxorubicin did not elicit these effects. The combination
treatment of chloroquine and bortezomib followed by
doxorubicin was more effective than the use of lysosome
and proteasome inhibitors alone in inducing C/EBP-β
LIP (Additional file 8a-b), triggering the LIP-induced
CRT activation and ICD (Fig. 6a-f ).
Fig. 4 Chloroquine and bortezomib downregulate expression and activity of Pgp. MDA-MB-231 and JC cells were cultured for 24 h in the
absence (ctrl) or presence of the lysosome inhibitor chloroquine (CQ; 1 μM) or the proteasome inhibitor bortezomib (B; 1 μM), alone or in
combination. a. The relative expression of Pgp gene was measured by qRT-PCR. Data are presented as means±SD (n = 4). *p < 0.02: treated cells
vs ctrl cells; °p < 0.001: CQ + B-treated cells vs CQ/B-treated cells. b. Plasma-membrane extracts were probed for Pgp or immunoprecipitated with
an anti-nitrotyrosine antibody, then probed for Pgp (nitroPgp). The expression of pancadherin was used as control of equal membrane protein
loading. The figure is representative of 1 out of 3 experiments. c. Pgp activity was analyzed in duplicates by a spectrophotometric assay. Data are
presented as means±SD (n = 4). *p < 0.02: treated cells vs ctrl cells; °p < 0.002: CQ + B-treated cells vs CQ/B-treated cells. d. Doxorubicin efflux (i.e.
the change of intracellular doxorubicin concentration per unit of time; dc/dt) was measured in triplicates by a fluorimetric assay, in cells
incubated 10 min with increasing concentrations of doxorubicin to achieve the maximal velocity efflux (Vmax). Data are presented as means±SD
(n = 3). *p < 0.001: treated cells vs ctrl cells; °p < 0.001: CQ + B-treated cells vs CQ/B-treated cells
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When doxycycline was added to the culture medium
to induce C/EBP-β LIP (Additional file 8a-b), LIP
transcriptional activity on CRT promoter (Fig. 6a-c),
CRT translocation (Fig. 6d) and CRT-mediated ICD (Fig.
6e-f ) were higher compared to un-induced cells. The
maximal efficiency in increasing C/EBP-β LIP
(Additional file 8a-b) and CRT-dependent ICD (Fig.
6a-f ) was achieved in cells treated with doxycycline (that
induces C/EBP-β LIP), chloroquine and bortezomib (that
prevent C/EBP-β LIP degradation), and doxorubicin
(that elicits ER stress up-regulating endogenous C/EBP-β
LIP). These results suggest that maintaining a high level
of C/EBP-β LIP, which down-regulate Pgp and
up-regulate CRT, fully restores doxorubicin-dependent
cell death in vitro, by triggering ER stress-mediated
apoptosis and ICD.
The C/EBP-β LIP effector CHOP mediates ER stress
dependent apoptosis and immunogenic cell death in
response to chloroquine and bortezomib
As detailed above, the activation of C/EBP-β LIP by chloro-
quine and bortezomib has pleiotropic effects, including in-
creased apoptosis (Fig. 2) and NO production (Fig. 3),
decreased Pgp expression and activity (Fig. 4), increased
CRT translocation and ICD (Fig. 5, 6). We thus investigated
if all these events were dependent on the activation of ER
Fig. 5 C/EBP-β LIP induces calreticulin expression and immunogenic cell death. MDA-MB-231 cells were left untreated (−, ctrl) or transfected with
an empty pcDNA4/TO vector (em/empty), with a pcDNA4/TO expression vector encoding C/EBP-β LAP or C/EBP-β LIP, respectively. a. Whole cell
lysates were probed with an antibody recognizing both C/EBP-β LAP and LIP isoforms. The expression of β-tubulin was used as control of equal
protein loading. The figure is representative of 1 out of 3 experiments. b. ChIP was performed to evaluate the binding of LAP or LIP to the CRT
promoter (sites: 831–843; 1302–1313). no Ab: no anti-C/EBP-β antibody; bl: blank; DNA input: genomic DNA. The figure is representative of 1 out
of 3 experiments. c. The relative expression of CRT gene was measured in triplicates by qRT-PCR. Data are presented as means±SD (n = 3). *p <
0.001: LIP-expressing cells vs all the other experimental conditions. d. Whole cell lysates were probed with an anti-CRT antibody. The expression
of β-tubulin was used as control of equal protein loading. The figure is representative of 1 out of 3 experiments. e. Surface CRT was detected by
flow cytometry. The histograms represent the results obtained from 1 out of 3 experiments. f. Tumor cells were stained with PKH2-FITC, DC were
stained with an anti-HLA-DR-PE antibody. Tumor cells were co-incubated with DC for 24 h. Double-stained cells were counted by flow cytometry.
Data are presented as means±SD (n = 3). *p < 0.001: LIP-expressing cells vs all the other experimental conditions. g. T-lymphocytes were
co-cultured with DC after phagocytosis, then incubated with MDA-MB-231 cells. The percentage of CD8+CD107+T-cells was measured by flow
cytometry. Data are presented as means±SD (n = 3). *p < 0.001: LIP-expressing cells vs all the other experimental conditions
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stress-related pathways. To this aim, we transiently silenced
CHOP, a key mediator of ER stress-triggered cell death
[33–35] and a direct downstream effector of C/EBP-β LIP
[36], in MDA-MB-231 cells treated with chloroquine and
bortezomib. In cells treated with a non-targeting (scram-
bled) siRNA, the lysosome and proteasome inhibitor acti-
vated caspase 3, while in CHOP-silenced cells they did not
(Fig. 7a). We did not detect any differences in the expres-
sion and activity of NOS enzymes (Additional file 9a-b), in
the expression, nitration and activity of Pgp (Additional file
9c-e), in the amount of CRT mRNA and protein (Add-
itional file 9f-g) between scrambled-treated and
CHOP-silenced cells. By contrast, the amount of surface
CRT and the cell phagocytosis - that were increased in
Fig. 6 Lysosome and proteasome inhibitors and C/EBP-β LIP overexpression cooperate to induce doxorubicin-triggered immunogenic cell death.
MDA-MB-231 cells (−, ctrl) were stably transfected with a doxycycline-inducible vector encoding C/EBP-β LIP. Cells were cultured in the absence
(−) or presence (+) of doxycycline (doxy; 1 μg/ml) for 24 h, to induce C/EBP-β LIP. When indicated, cells were co-incubated with the lysosome
inhibitor chloroquine (CQ; 1 μM) or with the proteasome inhibitor bortezomib (B; 1 μM), alone or in combination, followed by 5 μM doxorubicin
(dox) for further 24 h. a. ChIP was performed to evaluate the binding of LIP to the CRT promoter (sites: 831–843; 1302–1313). no Ab: no anti-C/
EBP-β antibody; bl: blank; DNA input: genomic DNA. The figure is representative of 1 out of 3 experiments. b. The relative expression of CRT gene
was measured in triplicates by qRT-PCR. Data are presented as means±SD (n = 3). *p < 0.01: treatments vs un-induced, untreated (“- doxy,-”) cells;
°p < 0.05: “+ doxy” cells vs corresponding “- doxy” cells. c. Whole cell lysates were probed with an anti-CRT antibody. The expression of β-tubulin
was used as control of equal protein loading. The figure is representative of 1 out of 3 experiments. d. Surface CRT was detected by flow
cytometry. The histograms represent the results obtained from 1 out of 3 experiments. Anti-ISO: anti-isotype antibody. f. Tumor cells were stained
with PKH2-FITC, DC were stained with an anti-HLA-DR-PE antibody. Tumor cells were co-incubated with DC for 24 h. Double-stained cells were
counted by flow cytometry. Data are presented as means±SD (n = 3). *p < 0.002: treatments vs un-induced, untreated (“- doxy,-”) cells; °p < 0.001:
“+ doxy” cells vs corresponding “- doxy” cells. g. T-lymphocytes were co-cultured with DC after phagocytosis, then incubated with MDA-MB-231
cells. The percentage of CD8+CD107+T-cells was measured by flow cytometry. Data are presented as means±SD (n = 3). *p < 0.001: treatments vs
un-induced, untreated (“- doxy,-”) cells; °p < 0.001: “+ doxy” cells vs corresponding “- doxy” cells
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scrambled-treated cells exposed to chloroquine and borte-
zomib - remained comparable to untreated cells in
CHOP-silenced cells (Fig. 7b-c). This experimental set
allowed to discriminate the ER stress-dependent and the
ER stress-independent events, involved in the rescue of
doxorubicin efficacy.
High C/EBP-β LIP levels restore doxorubicin efficacy in
drug-resistant breast cancer xenografts
In line with the in vitro results, the growth of orthotopi-
cally implanted TetON JC tumors, that were completely
insensitive to doxorubicin, was reduced by the combin-
ation of chloroquine and bortezomib (Fig. 8a-b). In the
Fig. 7 CHOP silencing prevents apoptosis and immunogenic cell death induced by lysosome and proteasome inhibitors. MDA-MB-231 cells were
transfected with a non-targeting siRNA (scrambled; scr) or with a CHOP-targeting siRNAs pool (siCHOP). Cells were grown in fresh medium (ctrl)
or in a medium containing the lysosome inhibitor chloroquine (CQ; 1 μM) or the proteasome inhibitor bortezomib (B; 1 μM), alone or in
combination for 24 h. a. Whole cell lysates were probed with the indicated antibodies. The expression of β-tubulin was used as control of equal
protein loading. The figure is representative of 1 out of 3 experiments. b. Surface CRT was detected by flow cytometry. The histograms represent
the results obtained from 1 out of 3 experiments. Anti-ISO: anti-isotype antibody. c. Tumor cells were stained with PKH2-FITC, DC were stained
with an anti-HLA-DR-PE antibody. Tumor cells were co-incubated with DC for 24 h. Double-stained cells were counted by flow cytometry. Data
are presented as means±SD (n = 3). *p < 0.001: CQ/B/CQ + B-treated cells vs “scr, ctrl” cells; °p < 0.001: “siCHOP” cells vs corresponding “scr” cells
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absence of C/EBP-β LIP induction, doxorubicin slightly
increased the anti-tumor effects of chloroquine and bor-
tezomib. When C/EBP-β LIP was induced, chloroquine
and bortezomib produced a stronger reduction in tumor
growth, and the subsequent addition of doxorubicin elic-
ited a further decrease (Fig. 8a-b).
Un-induced tumors treated with chloroquine and borte-
zomib and C/EBP-β LIP-induced tumors not treated with
chloroquine and bortezomib had a comparable decrease in
tumor cell proliferation, and a comparable increase in ER
stress and apoptosis, as suggested by the staining for Ki67,
CHOP and active caspase 3. In parallel, tumors showed
Fig. 8 Combination of pharmacological and genetic approaches preserving C/EBP-β LIP restores doxorubicin efficacy in resistant xenografts. JC
cells, stably transfected with an inducible expression vector for C/EBP-β LIP (JC TetON LIP) were orthotopically implanted into 6 week-old female
balb/C mice. When indicated, animals received 1mg/ml doxycycline in the drinking water (+ doxy) to induce the intratumor LIP expression. Mice
were randomized into 4 groups (n = 10 animals/group) and treated once a week for 3 consecutive weeks (days 1, 6, 12 after randomization) as
follows: 1) control (ctrl) group, treated with 0.1 ml saline solution intraperitoneally (i.p.); 2) doxorubicin (D) group, treated with 5 mg/kg
doxorubicin i.p.; 3) chloroquine+bortezomib (CQ + B) group, treated with 10 mg/kg CQ per os and 0.25 mg/kg bortezomib i.p.; 4) chloroquine
+bortezomib+doxorubicin (CQ + B + D) group, treated with chloroquine+bortezomib, followed by doxorubicin after 24 h. a. Tumor growth was
monitored daily by caliper measurement. Data are presented as means±SD. *p < 0.001: all treatments vs “-doxy, ctrl” group; °p < 0.05: “+ doxy”
treatments vs corresponding “- doxy” treatments; #p < 0.001: “+ dox” treatments vs corresponding “- dox” treatments (days 9–18). b. Photographs
of representative tumors of each group. c. Sections of tumors from each group of animals were stained with hematoxylin and eosin (HE) or with
the indicated antibodies. Nuclei were counter-stained with hematoxylin (10× ocular lens, 20× or 63× objective). Bar = 10 μm
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decreased Pgp, increased CRT positivity, increased intratu-
mor infiltration of DC and cytotoxic T-lymphocytes (Fig.
8c; Additional file 10a). Also the production of IFN-γ from
draining lymph nodes, a marker of local immune system
activation, was increased (Additional file 10b). Tumors with
induced C/EBP-β LIP, treated with chloroquine and borte-
zomib followed by doxorubicin, displayed a further reduc-
tion in proliferation and Pgp expression, as well as a further
increase in ER stress, apoptosis, CRT positivity, intratumor
DC, cytotoxic T-lymphocytes (Fig. 8c, Additional file 10a),
IFN-γ production (Additional file 10b).
Of note, the combined treatments did not induce signs
of systemic toxicity, nor worsen the cardiac damage in-
duced by doxorubicin, according to the animals’ hemato-
chemical parameters (Additional file 11).
C/EBP-β LIP and calreticulin are both necessary to restore
immunogenic cell death in doxorubicin-resistant breast
cancers
The immunogenic effect of doxorubicin in vitro and in
vivo was strictly dependent on CRT: indeed, in JC clones
with induced C/EBP-β LIP but knocked-out for CRT
(Fig. 9a), doxorubicin was unable to induce CRT trans-
location on cell surface (Fig. 9b), tumor cell phagocytosis
(Fig. 9c) and CD8+CD107+T-lymphocytes expansion (Fig.
9d). Both KO-CRT and wild-type tumors had a reduced
growth in the presence of C/EBP-β LIP induction (Fig.
9e-f). However, while in C/EBP-β LIP-induced/
CRT-wild-type tumors, doxorubicin strongly reduced
tumor growth, the drug had significantly lower anti-tumor
efficacy in C/EBP-β LIP-induced/KO-CRT tumors (Fig.
9d-e). These results suggested that both C/EBP-β LIP and
CRT are necessary to restore the ICD-induced by doxo-
rubicin against drug-resistant/Pgp-positive breast cancers.
Discussion
Anthracycline-based chemotherapy is one of the
first-line treatment in TNBC, but half of the patients de-
velop resistance [2]. Effective strategies of chemosensiti-
zation are still an unmet need.
The resistance to doxorubicin is mostly mediated by
Pgp, which limits the intracellular accumulation of the
drug and the possibility of exerting its pleiotropic cyto-
toxic mechanisms, such as increasing NO levels, indu-
cing ER stress and ICD [5, 16, 17, 20]. Since Pgp can be
inhibited at transcriptional level by C/EBP-β LIP [5] and
at post-translational level by NO [14, 15], we set up a
strategy that increases at the same time C/EBP-β LIP
and NO upon treatment with doxorubicin, in order to
downregulate expression and activity of Pgp and over-
come the resistance to the drug in TNBC.
By screening different breast cancer cell lines, we found
that TNBC human and murine doxorubicin-resistant/
Pgp-positive cells did not induce C/EBP-β LIP in response
to doxorubicin, differently from doxorubicin-sensitive/
Pgp-negative cells. The absence of LIP, as documented in
other chemoresistant tumors [5, 27], was due to its mono-
and poly-ubiquitination, followed by lysosomal and pro-
teasomal degradation. Indeed, doxorubicin-resistant/
Pgp-positive TNBC MDA-MB-231 and JC cells displayed
the highest activity of lysosome and proteasome, coupled
with the lowest induction of C/EBP-β LIP upon doxorubi-
cin treatment. We thus employed lysosome and prote-
asome inhibitors as pharmacological tools able to prevent
C/EBP-β LIP degradation, either in basal conditions or
upon doxorubicin treatment.
The elevated expression of the lysosomal enzyme ca-
thepsin D has been already correlated with breast cancer
progression [37], opening the way to the design of cathep-
sin D inhibitors as potential anti-tumor agents [38]. In the
present work, we used chloroquine, a FDA-approved lyso-
some and autophagosome inhibitor [21] that exerts
anti-tumor effects against TNBC stem cells [39] and en-
hances the ER stress-dependent cell death by inhibiting
lysosome activity [40, 41].
Also the high activity of proteasome has been correlated
with poor prognosis in TNBC patients and poor response
to chemotherapy in vitro [42]. Proteasome inhibitors are
under evaluation as new therapeutic options in TNBC pa-
tients [43]. Our work may provide the rationale for the
combined use of lysosome and proteasome inhibitors, in
association with first-line therapy doxorubicin, against re-
sistant TNBC as a new combination treatment that acti-
vates pleiotropic mechanisms of cell killing.
First, by increasing C/EBP-β LIP/CHOP/TRB3/caspase 3
axis, chloroquine and bortezomib induced a ER
stress-dependent apoptosis with at least two mechanism.
Indeed, on the one hand chloroquine and bortezomib pre-
vented the lysosomal and proteasomal degradation of LIP,
as demonstrated by the abrogation of their effects in cells
co-incubated with lysosome or proteasome activators. On
the other hand, chloroquine, bortezomib and doxorubicin
all increase NO production [17, 29, 30]. NO in turn induces
ER stress [19], and activates CHOP and caspase 3 [44].
Since the NO donor SNP induced LIP as chloroquine and
bortezomib did, while the NO scavenger carboxy-PTIO
abrogated the effects of the lysosome and proteasome
inhibitors, we propose that chloroquine and bortezomib
increased C/EBP-β LIP either by preventing its degradation
via lysosome and proteasome, or by eliciting a
NO-dependent ER stress. The combination treatment with
chloroquine, bortezomib and doxorubicin boosted the acti-
vation of ER stress-dependent cell death in TNBC cells, re-
storing one of the cytotoxic mechanisms of doxorubicin.
Second, by increasing C/EBP-β LIP, chloroquine and bor-
tezomib down-regulated Pgp expression and increased
CRT. The down-regulation of Pgp allowed doxorubicin to
reach an intracellular concentration sufficient to activate
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the pro-apoptotic C/EBP-β LIP/CHOP/TRB3/caspase 3
pathway and to increase the synthesis of NO. The activa-
tion of ER stress-dependent cell death pathway and the in-
crease in NO promote the translocation of CRT from ER to
plasma-membrane. The up-regulation of CRT elicited by
C/EBP-β LIP at transcriptional level further enhanced this
process, contributing to restore ICD and to re-establish a
second cytotoxic mechanisms of doxorubicin.
Third, chloroquine and bortezomib increased the syn-
thesis of NO, a non-competitive inhibitor of Pgp [14, 15],
Fig. 9 Doxorubicin-triggered immunogenic cell death is dependent either on C/EBP-β LIP or calreticulin. JC TetON LIP cells, transduced with a non-
targeting (scrambled, scr) vector or with a knocking-out calreticulin (KOCRT) vector, were cultured in the absence (− doxy) or presence (+ doxy) of
doxycycline (1 μg/ml) for 24 h, to induce C/EBP-β LIP. When indicated, 5 μM doxorubicin (D) was added for 24 h further. a. Whole cell lysates were
probed with the indicated antibodies. The expression of β-tubulin was used as control of equal protein loading. The figure is representative of 1 out of
3 experiments. b. Surface CRT was detected by flow cytometry. The histograms represent the results obtained from 1 out of 3 experiments. c. Tumor
cells were stained with PKH2-FITC, DC were stained with an anti-HLA-DR-PE antibody. Tumor cells were co-incubated with DC for 24 h. Double-stained
cells were counted by flow cytometry. Data are presented as means±SD (n = 3). *p < 0.001: “+ doxy” cells vs “- doxy” cells; °p < 0.001: “KOCRT” cells vs
“scr” cells. d. T-lymphocytes were co-cultured with DC after phagocytosis, then incubated with JC cells. The percentage of CD8+CD107+T-cells was
measured by flow cytometry. Data are presented as means±SD (n = 3). *p < 0.001: “+ doxy” cells vs “- doxy” cells; °p < 0.001: “KOCRT” cells vs “scr” cells.
e. Cells were implanted orthotopically into 6 week-old female balb/C mice. When indicated, animals received 1mg/ml doxycycline in the drinking
water (+ doxy) to induce the intratumor LIP expression. Mice were randomized into 8 groups (n = 8 animals/group) treated on days 1, 6, 12 after
randomization: 4 groups received 0.1ml saline solution i.p. (left panel), 4 groups received 5mg/kg doxorubicin (D) i.p. (right panel). Tumor growth was
monitored daily by caliper measurement. Data are presented as means±SD. *p < 0.001: “+ doxy” cells vs “- doxy” cells; °p < 0.001: “KOCRT” cells vs “scr”
cells. f. Photographs of representative tumors of each group
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that reduced the Vmax of doxorubicin efflux through the
transporter. The role of NO in cancer is still controversial,
since it can act as a tumorigenic or anti-cancer agent [45,
46], an activator or suppressor of the DC and
T-lymphocytes [47], depending on the concentration and
temporal production. The most studied NOS enzyme in
TNBC has been NOS II, a negative prognostic factor [48]
and an inducer of resistance to docetaxel [49]. As demon-
strated by Dávila-González and coworkers, NOS II inhib-
ition, coupled to a constant expression of NOS III,
sensitized TNBC cells to docetaxel and activated the ER
stress-dependent pro-apoptotic transducers such as
CHOP [49]. This situation closely mimics the scenario of
TNBC cells treated with chloroquine and bortezomib,
where NOS II was undetectable, NOS III expression was
constant, cells were re-sensitized to doxorubicin and acti-
vated CHOP-dependent pathways. Of note, docetaxel is a
substrate of Pgp as doxorubicin [7]: it is possible that the
chemosensitization observed by Dávila-González and co-
workers was in part due to the reduced efflux of docetaxel,
consequent to the inhibition of Pgp elicited by NO. This
hypothesis is supported by our findings in TNBC cells
treated with chloroquine and bortezomib, that had in-
creased NO synthesis, reduced Pgp activity, decrease ef-
flux of the Pgp substrate doxorubicin.
Given the pleiotropic effects exerted by the combination
of chloroquine and bortezomib, we next investigated if all
the observed events were due to the C/EBP-β
LIP-mediated induction of ER stress. To this aim, we tran-
siently silenced CHOP, a downstream effector of C/EBP-β
LIP [36] and a promoter of ER stress-dependent cell death
[33–35]. The results obtained in silenced cells indicated
that the activation of the caspase 3 elicited by chloroquine
and bortezomib, the translocation of CRT and the conse-
quent ICD, were dependent on ER stress. These data were
in accord with several evidences demonstrating that ER
Fig. 10 Proposed molecular circuitries linking C/EBP-β LIP, NO and Pgp in breast cancer. Breast cancer doxorubicin-sensitive cells have high C/
EBP-β LIP/CHOP/TRB3/caspase 3-axis, low expression of P-glycoprotein (Pgp) and high expression of calreticulin, consequent to the high C/EBP-β
LIP levels. In these cells, doxorubicin (DOX) reaches intracellular concentrations sufficient to induce ER stress-dependent cell death and
immunogenic cell death. By contrast, doxorubicin-resistant cells have high lysosome and proteasome activities that down-regulates C/EBP-β LIP,
prevent the activation of C/EBP-β LIP/CHOP/TRB3/caspase 3-axis, decreases calreticulin expression and nitric oxide (NO) production. These events
determine high expression and activity of Pgp and abrogate the efficacy of doxorubicin. The combined inhibition (I) of lysosome and proteasome
with chloroquine (CQ) and bortezomib (B) restores the C/EBP-β LIP/CHOP/TRB3/caspase 3-axis and the synthesis of NO, lowering expression and
activity of Pgp, increasing transcription and translocation to the plasma-membrane of calreticulin. This rewiring restores the mechanisms of
doxorubicin’s induced cell death via ER stress and immunogenic cell death, overcoming drug resistance in vitro and in vivo
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stress induces apoptosis via CHOP [50], triggers the sur-
face translocation of CRT and the CRT-mediated phago-
cytosis [3, 6]. By contrast, ER stress was not responsible
for the increased production of NO, the reduction in Pgp
expression and activity, the up-regulation of CRT gene. In-
deed, the increase in NO was due to the higher expression
of NOS I induced by bortezomib and to the higher activity
of NOS III induced by chloroquine. The down-regulation
of Pgp and the up-regulation of CRT were caused by the
activity of C/EBP-β LIP as transcription factor. The re-
duced activity of Pgp was consequent to the increased
production of NO that nitrated tyrosine residues critical
for the pump’s catalytic activity.
We can conclude that the effects of chloroquine and
bortezomib were either ER stress-dependent or inde-
pendent, but they all triggered virtuous circuitries that
effectively overcome the resistance to doxorubicin in
Pgp-positive TNBC cells.
The effects of choloroquine and bortezomib observed
in vitro were well reproduced in the preclinical model of
doxorubicin-resistant/Pgp-positive JC tumors.
The use of chloroquine and bortezomib in TNBC is
not new. It has been reported that chloroquine chemo-
sensitizes TNBC-derived xenografts at 50 mg/kg [49], i.e.
five-fold the concentration used in the present study.
Bortezomib partially reduced tumor growth in TNBC
patient-derived xenografts at 0.75 mg/kg [51], i.e.
three-fold the dosage used in our in vivo protocol. In
chemoresistant TNBC patients bortezomib achieved a
partial response, followed by disease recurrence [42].
The novelty of our approach is the use of lower doses
of chloroquine and bortezomib in combination with
doxorubicin. Such combination therapy did not elicit
systemic toxicity, but it reduced tumor growth, in-
creased intratumor ER stress, apoptosis, CRT expres-
sion, DC and CD8+T-lymphocyte infiltration. The
intratumor activation of C/EBP-β LIP further en-
hanced the responses elicited by the chloroquine
/bortezomib/doxorubicin combination, confirming that
C/EBP-β LIP and its downstream effectors (such as
CHOP and caspase 3) are critical factors in overcom-
ing doxorubicin resistance.
An anti-tumor abundant immune-infiltrate, indicated
by high CD8+T-lymphocytes and low T-regulatory cells,
is a strong predictor of good response to chemotherapy
in breast cancer patients [52, 53], suggesting that part of
the anti-tumor effects of anthracyclines is mediated by
the engagement of the host immune system. In agree-
ment with this hypothesis, knocking-out CRT in tumors
with induced C/EBP-β LIP completely abrogated the
doxorubicin-induced ICD and reduced doxorubicin
anti-tumor efficacy, indicating that both C/EBP-β LIP
and CRT are necessary for a full rescue of doxorubicin
efficacy in resistant tumors.
Conclusions
In summary, we suggest that the high activities of lysosome
and proteasome – that down-regulated C/EBP-β LIP and
LIP/CHOP/TRB3/caspase 3-axis – and the low production
of NO are hallmarks of Pgp-positive TNBC and inducers of
doxorubicin resistance. The combined use of chloroquine
and bortezomib increases at the same time C/EBP-β LIP
and NO levels: this condition restores the ER-dependent/
CHOP-mediated apoptosis, down-regulates Pgp expression
and activity, increases CRT expression and translocation to
the plasma-membrane, re-activates the DC/CD8+T-lym-
phocyte response against the tumor upon doxorubicin
treatment (Fig. 10). Since either chloroquine or bortezomib
are already approved for clinical use, our work may open
the way to their repurposing as adjuvant agents in patients
with TNBC resistant to anthracyclines.
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